长春氟宁治疗上尿路尿路上皮癌——一项观察性研究的亚组分析

Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study.

作者信息

Heers Hendrik, DE Geeter Patrick, Goebell Peter J, Matz Ullrich, DE Schultz Wito, Edlich Birgit, Retz Margitta, Hegele Axel

机构信息

Department of Urology/Pediatric Urology, Philipps University, Marburg, Germany.

Department of Urology, Kassel Hospital, Kassel, Germany.

出版信息

Anticancer Res. 2017 Nov;37(11):6437-6442. doi: 10.21873/anticanres.12098.

DOI:10.21873/anticanres.12098

PMID:29061830

Abstract

BACKGROUND/AIM: Despite an expected prognostic disadvantage for upper tract versus lower tract metastatic urothelial carcinomas (UTUC/LTUC), only few studies have been conducted to elucidate potential differences in chemotherapy treatment.

PATIENTS AND METHODS

A post-hoc subgroup analysis of a non-interventional study investigating vinflunine after failure of a platinum-based chemotherapy in metastatic/locally advanced UC patients was performed.

RESULTS

A total of 18 and 59 out of 77 patients had UTUC and LTUC, respectively. The effectiveness of vinflunine treatment was comparable with an overall response rate of 22.2% and 23.7% respectively and a median progression-free survival of 2.76 months in both groups. Median overall survival was 5.0 months in UTUC compared to 8.2 months in the LTUC group (p=0.478). The safety profile was in accordance with previous vinflunine experiences, with a comparable frequency of adverse events in both groups.

CONCLUSION

Vinflunine can be applied in the 2nd line for UC regardless of the primary tumor localization.

摘要

背景/目的：尽管上尿路转移性尿路上皮癌（UTUC）相对于下尿路转移性尿路上皮癌（LTUC）在预后方面预期处于劣势，但仅有少数研究致力于阐明化疗治疗中的潜在差异。

患者与方法

对一项非干预性研究进行事后亚组分析，该研究在转移性/局部晚期尿路上皮癌（UC）患者铂类化疗失败后使用长春氟宁。

结果

77例患者中，分别有18例和59例患有UTUC和LTUC。长春氟宁治疗的有效性相当，两组的总缓解率分别为22.2%和23.7%，中位无进展生存期均为2.76个月。UTUC组的中位总生存期为5.0个月，而LTUC组为8.2个月（p = 0.478）。安全性与既往长春氟宁的使用经验一致，两组不良事件发生率相当。